Production of live attenuated influenza vaccines against seasonal and potential pandemic influenza viruses.
Vaccination remains the most effective means to prevent morbidity and mortality caused by influenza epidemics and pandemics. Live attenuated influenza vaccine (LAIV) has been proven to be effective in preventing influenza with broad cross reactivity to drifted strains. Owing to the sophisticated nature of the influenza vaccine production process, the time needed to develop high yield LAIV strains for vaccine production and product release remains a constant challenge. This review summarizes LAIV production process with highlights on the experiences gained during the past decade generating seasonal and pandemic LAIV seeds by reverse genetics strategy.
MedImmune LLC, 319 North Bernardo Avenue, Mountain View, CA 94043, United States. Electronic address: jinh@medimmune.com.
Hong
H
Jin
MedImmune LLC, 319 North Bernardo Avenue, Mountain View, CA 94043, United States.
Zhongying
Z
Chen
D000818:Animals; D001709:Biotechnology; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D009975:Orthomyxoviridae / Q000145:classification / Q000235:genetics / Q000276:immunology*; D014613:Vaccines, Attenuated
D007252:Influenza Vaccines; D014613:Vaccines, Attenuated